{
    "clinical_study": {
        "@rank": "73715", 
        "arm_group": [
            {
                "arm_group_label": "Placebo (left) / Cromoglicate (right)", 
                "arm_group_type": "Other", 
                "description": "Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)"
            }, 
            {
                "arm_group_label": "Placebo (right) / Cromoglicate (left)", 
                "arm_group_type": "Other", 
                "description": "Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this exploratory study is to investigate the clinical efficacy of study drug\n      (LP0074) in the treatment of Mastocytosis. The trial will be performed as a left/right\n      comparison study in male/female subjects with mastocytosis, in a prospective,\n      double-blinded, randomised, single centre setting."
        }, 
        "brief_title": "Cromoglicate in Mastocytosis", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Mastocytosis", 
        "condition_browse": {
            "mesh_term": [
                "Mastocytosis", 
                "Urticaria Pigmentosa"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent has been obtained\n\n          -  Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic\n             mastocytosis with skin involvement and a positive Darier's Sign\n\n          -  Age between 18 and 70 years\n\n          -  Either sex\n\n          -  Any race or ethnicity\n\n          -  Attending hospital outpatient clinic or the private practice of a dermatologist.\n\n        Exclusion Criteria:\n\n          -  The presence of autoimmune and infectious disease including aggressive systemic\n             mastocytosis\n\n          -  Medical history or presence of epilepsy, significant neurological disorders,\n             cerebrovascular attacks or ischemia\n\n          -  Medical history or presence of myocardial infarction or cardiac arrhythmia which\n             requires drug therapy, hyper/hypokalemia\n\n          -  Evidence of severe renal dysfunction (creatinine > 1,5 times upper reference value)\n\n          -  Evidence of significant hepatic disease (liver enzymes > 2 times upper reference\n             value)\n\n          -  Presence of active cancer which requires chemotherapy or radiation therapy\n\n          -  Commitment to an institution in terms of \u00a7 40 Abs. 1 S. 3 Nr. 4 AMG\n\n          -  Intake of antihistamines or leukotriene antagonists within 7 days prior to the\n             beginning of the study\n\n          -  Intake of oral corticosteroids within 14 days prior to randomisation\n\n          -  Use of depot corticosteroids or chronic systemic corticosteroids within 21 days prior\n             to randomisation\n\n          -  Radiation therapy of target areas including UV therapy within 4 weeks prior to\n             randomisation\n\n          -  Confounding other dermatological diseases or conditions that can affect the symptoms\n             of the target areas\n\n          -  Known or suspected hypersensitivity to component(s) of investigational products.\n\n          -  Current participation in any other interventional clinical trial.\n\n          -  Subjects who have received treatment with any nonmarketed drug substance (i.e. an\n             agent which has not yet been made available for clinical use following registration)\n             within the last 4 weeks or 5 half-lives (whichever is longer) prior to randomisation\n\n          -  Previously randomised in this clinical trial\n\n          -  In the opinion of the investigator, the subject is unlikely to comply with the\n             Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state).\n\n          -  Females who are pregnant, of child-bearing potential and wishing to become pregnant\n             during the trial or are breast feeding.\n\n          -  Females of child-bearing potential with positive pregnancy test at visit 1.\n\n          -  Subjects (or their partner) not using an adequate method of contraception (according\n             to national requirements, as applicable)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701843", 
            "org_study_id": "LP0074-33"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo (left) / Cromoglicate (right)", 
                    "Placebo (right) / Cromoglicate (left)"
                ], 
                "description": "Twice daily topical treatment for 14 days", 
                "intervention_name": "Cromoglicate", 
                "intervention_type": "Drug", 
                "other_name": "cromoglicate"
            }, 
            {
                "arm_group_label": [
                    "Placebo (left) / Cromoglicate (right)", 
                    "Placebo (right) / Cromoglicate (left)"
                ], 
                "description": "Twice daily topical treatment for 14 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cromolyn Sodium"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "D-10117"
                }, 
                "name": "Allergie-Centrum-Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9 - Universit\u00e4tsmedizin Berlin"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis", 
        "overall_official": {
            "affiliation": "Allergie-Centrum-Charit\u00e9", 
            "last_name": "Frank Siebenhaar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of mechanically induced changes of lesions", 
            "safety_issue": "No", 
            "time_frame": "Baseline to week 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Evaluation of mechanically induced wheal and flare response", 
            "safety_issue": "No", 
            "time_frame": "Baseline to week 2"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013", 
        "why_stopped": "prematurely terminated because of low recruitment"
    }
}